Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've been buying more FDVF today. It looks very inexpensive here.
Sooner or later the PFHO buyers are going to exhaust this PFHO seller. I would think the stock is good for a move upwards after that.
Tel-Instrument Electronics Corp. to Host Conference Call to Discuss Fiscal Fourth Quarter 2015 Results
Tel-Instrument Electronics Corp. (“TIC” or the “Company”) (NYSE MKT: TIK) will host a conference call and webcast on Thursday, June 25, 2015 at 9:00 a.m. Eastern Time to discuss the Company’s fiscal fourth quarter results.
To access the live webcast, log onto the Tel-Instrument Electronics’ website at https://www.telinstrument.com/learn-about-telinstrument/investor-relations.html.
To participate in the call by phone, dial (877) 407-8035 approximately five minutes prior to the scheduled start time. International callers please dial (201) 689-8035.
A replay of the teleconference will be available until July 25, 2015 and may be accessed by dialing (877) 660-6853. International callers may dial (201) 612-7415. Callers should use conference ID: 13612604.
About Tel-Instrument Electronics Corp.
Tel-Instrument is a leading designer and manufacturer of avionics test and measurement solutions for the global commercial air transport, general aviation, and government/military aerospace and defense markets. Tel-Instrument provides instruments to test, measure, calibrate, and repair a wide range of airborne navigation and communication equipment. For further information please visit our website at www.telinstrument.com.
This press release includes statements that are not historical in nature and may be characterized as “forward-looking statements,” including those related to future financial and operating results, benefits, and synergies of the combined companies, statements concerning the Company’s outlook, pricing trends, and forces within the industry, the completion dates of capital projects, expected sales growth, cost reduction strategies, and their results, long-term goals of the Company and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends, and similar expressions concerning matters that are not historical facts. All predictions as to future results contain a measure of uncertainty and, accordingly, actual results could differ materially. Among the factors which could cause a difference are: changes in the general economy; changes in demand for the Company’s products or in the cost and availability of its raw materials; the actions of its competitors; the success of our customers; technological change; changes in employee relations; government regulations; litigation, including its inherent uncertainty; difficulties in plant operations and materials; transportation, environmental matters; and other unforeseen circumstances. A number of these factors are discussed in the Company’s previous filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150622005983/en/
Contact:
Tel-Instrument Electronics Corp.
Joseph P. Macaluso, 201-933-1600
or
Institutional Marketing Services (IMS)
John Nesbett or Jennifer Belodeau
203-972-9200
jnesbett@institutionalms.com
XPEL Technologies (DAP-U.V / XPLT) is a rapidly growing provider of automotive paint protection film that I think has potential to be a multi-bagger from the current price. Below is a summary of my thesis:
1. XPEL has had massive growth over many years. Below is the history of revenue and EPS:
Year Revenue EPS
2014 $29,630,179 $0.12
2013 $17,898,812 $0.05
2012 $10,670,838 $0.05
2011 $6,041,853 $0.03
2010 $4,129,964 $0.02
2009 $3,834,565 -$0.02 (EPS was $0.01 from continuing operations)
You must be drinking too as your math needs some work.
Buy 1500 shares of XPLT / DAP-U.V at $3.0485 for the SwingTrade Portfolio. I'll post some DD soon.
Buy 50 shares of PFHO for the SwingTrade Portfolio at $29.50.
I've been buying more PFHO. It looks very cheap here IMO.
Vexigo's Visualizr Supports New Mobile Friendly Search Engine Ranking Requirements
TEL AVIV, Israel and RIVER EDGE, New Jersey, June 18, 2015 /PRNewswire/ --
Vexigo, a global provider of online video advertising and content monetization solutions and a wholly- owned subsidiary of Mer Telemanagement Solutions Ltd. (MTSL), announced today that its Visualizr mobile publishing platform, which transforms sites so they are mobile friendly thus increasing targeted ad exposure and generating higher ad revenue; now fully supports and leverages the recent changes to search engine ranking algorithms that favor mobile friendly websites.
The Vexigo Visualizr mobile publishing platform enables website owners and publishers to promote and monetize their content as a personalized magazine optimized for all types of devices, including mobile and wearable devices. Vexigo's patented contextual analysis engine performs real-time analysis of a website visitors' navigation behavior and automatically pushes relevant website elements and content for each unique visitor to their device creating a stunning, personalized mobile website.
"Many publishers and online advertisers are struggling with the recent ranking changes that major search engines like Google Inc. and Microsoft Corporation recently implemented that boost the search ranking of mobile friendly pages while penalizing those pages that are not mobile friendly," said Dan Gilai, Director of Product Management at Vexigo. "The Visualizr platform enables both publishers and advertisers to take advantage of a personalized, mobile friendly platform that dynamically restyles content that is the most relevant to each visitor resulting in a content rich, personalized mobile experience."
Content publishers and advertisers can quickly take advantage of Visualizr's full suite of mobile online advertising options, including native ads, interstitials, video, rich media and sponsored content that enables them to target their audience with pinpoint accuracy. In addition, the solution provides website visitors with personalized content, based on their unique reading preferences and usage increasing visitor stickiness and time spent on the site. The Visualizr platform also includes a management dashboard for full visibility into engagement statics and ROI measurements allowing publishers to quickly optimize their content and monetization efforts.
About Vexigo
Vexigo Ltd. (http://www.vexigo.com) is a global provider of content visualization and video advertising software and services that deliver compelling results through a propriety in-house technology and an easy-to-use publishing platform specifically designed for content publishers. The Vexigo solution for online and mobile platforms supports multiple ad formats and interactive ad units with a cutting-edge optimization platform providing precise targeting in a safe environment for both advertisers and website owners. For more information, please visit the Vexigo Visualizr web site: http://www.visualizr.me.
Vexigo is a division of Mer Telemanagement Solutions Ltd. ("MTS") (MTSL), a provider of innovative products and services for telecom expense management (TEM), enterprise mobility management (EMM), mobile virtual network operators and enablers (MVNO/MVNE), billing mobile money services and solutions and an IOT/M2M enablement platform used by mobile service providers.
Headquartered in Israel, MTS markets its solutions through wholly owned subsidiaries in Israel, the United States and Hong Kong and through distribution channels. MTS shares are traded on the NASDAQ Capital Market (symbol MTSL). For more information, please visit the MTS web site: http://www.mtsint.com.
Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, risks in product development plans and schedules, rapid technological change, changes and delays in product approval and introduction, customer acceptance of new products, the impact of competitive products and pricing, market acceptance, the lengthy sales cycle, proprietary rights of the Company and its competitors, risk of operations in Israel, government regulations, dependence on third parties to manufacture products, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission.
Company Contact:
Vexigo
Phone: +972-(722)-410-118
Email: visualizr@vexigo.com
Websites: http://www.vexigo.com and http://www.visualizr.me
TIK and MTSL are getting more love.
RX.V / BIOYF continues its robotic move north.
I've heard of them but I'm not following them. Should I?
RX.V / BIOYF continues to rip higher. The last trade today was at C$8.26 / US$6.71!
The uptick in RX.V / BIOYF continues.
RX.V / BIOYF continues to move up.
Buy 50 shares of PSIX for the SwingTrade Portfolio at $53.17.
RX.V / BIOYF has been getting some love.
Orion Energy Systems to Move to NASDAQ Capital Market
Orion Energy Systems, Inc. (NYSE MKT:OESX), June 3, 2015 - a leading designer and manufacturer of high-performance, energy-efficient retrofit lighting platforms, today announced it will voluntarily transfer its stock exchange listing from the NYSE MKT to the NASDAQ Capital Market effective June 15, 2015. The last day of trading on the NYSE MKT is expected to be June 12, 2015.
Orion’s stock will continue to trade under the ticker symbol OESX.
“We believe that listing on the NASDAQ Capital Market supports the upward direction of our company and offers the best platform of services for investing in Orion,” said Orion's Chief Executive Officer, John Scribante.
About Orion Energy Systems
Orion is leading the transformation of commercial and industrial buildings with state-of-the-art energy efficient lighting systems and retrofit lighting solutions. Orion manufactures and markets a cutting edge portfolio of products encompassing LED Solid-State Lighting and high intensity fluorescent lighting. Many of Orion's 100+ granted patents and pending patent applications relate to lighting systems that provide exceptional optical and thermal performance, which drive financial, environmental, and work-space benefits for a wide variety of customers in the retrofit markets.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150603006635/en/
Contact:
Investor Relations:
Orion Energy Systems, Inc.
Scott Jensen, (920) 892-9340
Chief Financial Officer
or
Media Relations:
Orion Energy Systems, Inc.
Erica St. Angel, (920) 892-5653
SVP Marketing
MTSL is screaming higher.
I'm glad I purchased more PFHO shares today. There was an 8-K after the bell. :)
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10733150-902-6816&type=sect&TabIndex=2&companyid=169229&ppu=%252fdefault.aspx%253fcik%253d1138476
I'm glad I purchased more shares today. There was an 8-K after the bell. :)
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=10733150-902-6816&type=sect&TabIndex=2&companyid=169229&ppu=%252fdefault.aspx%253fcik%253d1138476
Milestone Scientific Announces Approval for Listing on the NYSE MKT
LIVINGSTON, NJ--(Marketwired - May 28, 2015) - Milestone Scientific Inc. (MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of listing requirements. Trading on the NYSE MKT is expected to commence on June 1, 2015. The Company will continue to trade under the symbol "MLSS."
"Trading on the NYSE MKT is an important development for the Company and reflects our continued progress as we move forward with our medical instruments. These instruments represent a leap forward in drug delivery technology, which remained relatively unchanged since the invention of the hypodermic syringe in the 1800s. Our computer-controlled instruments are designed to provide safe, controlled and painless injections, as well as help reduce costs and malpractice risk for healthcare professionals," commented Leonard Osser, CEO of Milestone Scientific. "Listing on the NYSE MKT should provide the Company increased exposure within the investment community and improved liquidity."
NYSE MKT is a fully integrated trading venue within the NYSE community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE community.
"We welcome Milestone Scientific to the NYSE MKT family of listed companies," said Garvis Toler, Global Head of Capital Markets, NYSE. "Milestone will be joining other well-known medical device companies taking advantage of the NYSE's advanced and innovative market model to offer a premier value for listing and trading their stocks."
About Milestone Scientific
Milestone Scientific Inc. (MLSS) is a medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
David Waldman or Klea Theoharis
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
Thanks for your post, hasagos. I'm glad you enjoy this board. SRMC has been on my radar. I've owned them before.
Sell 2000 shares of SLGD at $1.47 for the SwingTrade Portfolio.
OML.V - Omni-Lite Signs Long-Term Letter of Agreement with Current Automotive Customer
- Revenues increase by 25% in first four months of 2015
- Production output increases 37% in first four months
- Omni-Lite receives large forging system back from Japan
- US$577,413 in new contracts announced
http://finance.yahoo.com/news/omni-lite-signs-long-term-123000279.html
"I Passed on Berkshire Hathaway at $97 Per Share" by Rod MacIver
http://microcapclub.com/2015/05/i-passed-on-berkshire-hathaway-at-97-per-share/
Wow! $RX.V / $BIOYF is up 12% at the moment!
"Cutting Your Losses" is an excellent article by Ian Cassel
http://microcapclub.com/2015/05/cutting-your-losses/
Buy 300 shares of BIOYF/RX.V at US$5.70 for the SwingTrade Portfolio.
MTSL prints $2.93!
A nice Seeking Alpha article is out on MTSL.
http://seekingalpha.com/article/3195306-mer-telemanagement-vexigo-acquisition-brings-a-return-to-profitability-and-upside-potential
I do not like CSTI at the moment but I am very dynamic in my opinion and will change my opinion if warranted. After the report today I feel like it is a difficult company to handicap. A wide variety of results going forward would not surprise me.
Sell 200 shares of CSTI for the SwingTrade Portfolio at $12.11.
OncoSec Medical Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
SAN DIEGO, May 14, 2015 /PRNewswire/ -- OncoSec Medical Inc. ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Secretary of State of Nevada on May 18, 2015 and the company's common stock will begin trading on a split-adjusted basis upon Financial Industry Regulatory Authority (FINRA) approval.
"This reverse stock split represents a critical milestone for OncoSec as we intend to uplist to a national securities exchange to attract a broader, more diverse shareholder base," said Punit Dhillon, CEO and President of OncoSec. "We believe that this is the next logical step for our company as we continue to enhance our intratumoral immunotherapy technology and advance our clinical pipeline. With the support of our shareholders, we look forward to validating our ImmunoPulse™ technology in clinical and preclinical studies, generating more value for our investors, and securing our place in this long-awaited revolution in cancer treatment."
At the effective time of the 1-for-20 reverse stock split, every 20 shares of issued and outstanding common stock will be converted into 1 share of issued and outstanding common stock, and the authorized shares of common stock will be reduced from 3,200,000,000 to 160,000,000 shares. All fractional shares of common stock will be rounded up to the nearest whole share. Immediately after the reverse stock split becomes effective, the company will have approximately 12,350,132 shares of common stock outstanding.
OncoSec's common stock will trade under the ticker symbol "ONCSD" for a period of 20 business days after the reverse stock split has been effected in the marketplace, and the common stock will also trade under a new CUSIP number of 68234L207. Before any listing of the common stock on the NASDAQ Capital Market could occur, NASDAQ will need to approve the company's application for listing after the reverse stock split is completed.
Shareholders of record are not required to send in their current stock certificates or evidence of book-entry or other electronic positions for exchange. Following the effectiveness of the reverse stock split, each stock certificate and book-entry or other electronic position representing issued and outstanding shares of the company's common stock will be automatically adjusted. Those shareholders holding common stock in "street name" will receive instructions from their brokers if they need to take any action in connection with the reverse stock split.
If a shareholder holding a paper stock certificate would like to send the certificate to the company's transfer agent for exchange, then the transfer agent will issue a new stock certificate reflecting the terms of the reverse stock split to such requesting shareholder. In that event, stock certificates could be mailed to the company's transfer agent at the following address:
Nevada Agency and Transfer Company
50 West Liberty Street, Suite 880
Reno, Nevada 89501
All of the company's options, warrants, and other convertible securities that are outstanding immediately before the reverse stock split will also be adjusted by dividing the number of shares of common stock into which the options, warrants, and other convertible securities are exercisable or convertible by 20 and multiplying the exercise or conversion price thereof by 20, all in accordance with the terms of the plans, agreements, or arrangements governing such options, warrants, and other convertible securities.
For additional insight into the company's reverse stock split and future plans, please visit the "CEO's Perspective" on OncoSec's website: http://oncosec.com/ceo-perspective-reverse-split-and-uplisting.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse™ have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response limiting the systemic toxicities associated with other treatments. OncoSec's lead program evaluating ImmunoPulse™ for the treatment of metastatic melanoma is currently in Phase II development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse™ in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements," including statements regarding, among other things, the effectiveness of the reverse stock split, including FINRA's approval thereof, the company's plans to list its common stock on the NASDAQ Capital Market, or any other national securities exchange, and the impact the reverse stock split or any such listing may have on the company's business, prospects and/or stock price. Forward-looking statements are based on management's current views, assumptions and preliminary expectations and are subject to risks and uncertainties, which may cause actual results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include the timing and decisions of regulators regarding proposed company actions, which are largely out of our direct control, our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
CTIG earnings weren't as good as last quarter.
The USNU quarter was decent. Earnings would have been better if it weren't for the loss in their unconsolidated entity of $36K. SG&A was slightly higher and they probably were impacted a bit by the weather. They have a stellar balance sheet. IMO this is overdone.
There is a 2,093 share bid on PFHO at $35.03.
Sell 5000 shares of CTIG for $0.4550 for the SwingTrade Portfolio.